

# Roger J Packer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2114103/publications.pdf>

Version: 2024-02-01

314  
papers

30,232  
citations

2795

94  
h-index

5364

164  
g-index

325  
all docs

325  
docs citations

325  
times ranked

15726  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4202-4208.	0.8	834
2	Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. <i>Journal of Neurosurgery</i> , 1996, 85, 56-65.	0.9	695
3	Metastasis Stage, Adjuvant Treatment, and Residual Tumor Are Prognostic Factors for Medulloblastoma in Children: Conclusions From the Children's Cancer Group 921 Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 832-832.	0.8	674
4	Study design and cohort characteristics of the childhood cancer survivor study: A multi-institutional collaborative project. <i>Medical and Pediatric Oncology</i> , 2002, 38, 229-239.	1.0	632
5	Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. <i>Journal of Neurosurgery</i> , 1997, 86, 747-754.	0.9	562
6	Treatment of Children With Medulloblastomas With Reduced-Dose Craniospinal Radiation Therapy and Adjuvant Chemotherapy: A Children's Cancer Group Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 2127-2127.	0.8	554
7	The Childhood Cancer Survivor Study: A National Cancer Institute–Supported Resource for Outcome and Intervention Research. <i>Journal of Clinical Oncology</i> , 2009, 27, 2308-2318.	0.8	551
8	New Primary Neoplasms of the Central Nervous System in Survivors of Childhood Cancer: a Report From the Childhood Cancer Survivor Study. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1528-1537.	3.0	492
9	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. <i>Acta Neuropathologica</i> , 2016, 131, 821-831.	3.9	478
10	Intellectual Outcome After Reduced-Dose Radiation Therapy Plus Adjuvant Chemotherapy for Medulloblastoma: A Children's Cancer Group Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 3470-3476.	0.8	476
11	Long-Term Outcomes Among Adult Survivors of Childhood Central Nervous System Malignancies in the Childhood Cancer Survivor Study. <i>Journal of the National Cancer Institute</i> , 2009, 101, 946-958.	3.0	450
12	Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the nf1 optic pathway glioma task force. <i>Annals of Neurology</i> , 1997, 41, 143-149.	2.8	434
13	Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. <i>Journal of Neurosurgery</i> , 1994, 81, 690-698.	0.9	425
14	Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. <i>Nature Genetics</i> , 2001, 29, 143-152.	9.4	421
15	Multiagent Chemotherapy and Deferred Radiotherapy in Infants With Malignant Brain Tumors: A Report From the Children's Cancer Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 7621-7631.	0.8	381
16	Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. <i>Journal of Clinical Oncology</i> , 2015, 33, 2646-2654.	0.8	368
17	Chronic Disease in the Childhood Cancer Survivor Study Cohort: A Review of Published Findings. <i>Journal of Clinical Oncology</i> , 2009, 27, 2339-2355.	0.8	360
18	Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 2641-2647.	0.8	348

#	ARTICLE	IF	CITATIONS
19	Psychological Outcomes in Long-Term Survivors of Childhood Brain Cancer: A Report From the Childhood Cancer Survivor Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 999-1006.	0.8	346
20	Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors. <i>Cancer</i> , 2003, 97, 663-673.	2.0	342
21	Late-Occurring Stroke Among Long-Term Survivors of Childhood Leukemia and Brain Tumors: A Report From the Childhood Cancer Survivor Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 5277-5282.	0.8	337
22	A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. <i>Journal of Neurosurgery</i> , 1989, 70, 707-713.	0.9	324
23	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1011-1022.	5.1	315
24	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1200-1207.	5.1	307
25	Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. <i>Journal of Neurosurgery</i> , 1998, 88, 695-703.	0.9	303
26	Long-Term Neurologic and Neurosensory Sequelae in Adult Survivors of a Childhood Brain Tumor: Childhood Cancer Survivor Study. <i>Journal of Clinical Oncology</i> , 2003, 21, 3255-3261.	0.8	298
27	Intracranial Germ Cell Tumors. <i>Oncologist</i> , 2000, 5, 312-320.	1.9	285
28	Neurocognitive status in long-term survivors of childhood CNS malignancies: A report from the Childhood Cancer Survivor Study.. <i>Neuropsychology</i> , 2009, 23, 705-717.	1.0	281
29	Low-Stage Medulloblastoma: Final Analysis of Trial Comparing Standard-Dose With Reduced-Dose Neuraxis Irradiation. <i>Journal of Clinical Oncology</i> , 2000, 18, 3004-3011.	0.8	275
30	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	5.1	274
31	Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group Trial No. CCG-945. <i>Journal of Neurosurgery</i> , 1998, 89, 52-59.	0.9	273
32	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	13.7	266
33	Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: An update. <i>Annals of Neurology</i> , 1988, 23, 79-85.	2.8	260
34	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. <i>Journal of Clinical Oncology</i> , 2018, 36, 1963-1972.	0.8	250
35	Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. <i>Neuro-Oncology</i> , 2012, 14, 790-797.	0.6	248
36	Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. <i>Neurology</i> , 2005, 64, 553-555.	1.5	242

#	ARTICLE	IF	CITATIONS
37	Medulloblastoma in childhood: new biological advances. <i>Lancet Neurology</i> , The, 2007, 6, 1073-1085.	4.9	239
38	A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. <i>Neuro-Oncology</i> , 2017, 19, 1135-1144.	0.6	236
39	Optic pathway and hypothalamic/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up. <i>Cancer</i> , 1995, 75, 1051-1059.	2.0	234
40	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 2934-2941.	0.8	232
41	Pediatric high-grade glioma: biologically and clinically in need of new thinking. <i>Neuro-Oncology</i> , 2017, 19, now101.	0.6	217
42	Long-term sequelae of cancer treatment on the central nervous system in childhood. <i>Medical and Pediatric Oncology</i> , 1987, 15, 241-253.	1.0	212
43	Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. <i>Neuro-Oncology</i> , 2013, 15, 97-103.	0.6	212
44	Neoadjuvant chemotherapy for newly diagnosed germ-cell tumors of the central nervous system. <i>Journal of Neurosurgery</i> , 1987, 67, 65-70.	0.9	202
45	Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. <i>Journal of Neuro-Oncology</i> , 1995, 24, 21-28.	1.4	201
46	Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. <i>Nature Communications</i> , 2016, 7, 11185.	5.8	197
47	Long-term outcomes of adult survivors of childhood cancer. <i>Cancer</i> , 2005, 104, 2557-2564.	2.0	192
48	Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor <i>MYBL1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 8188-8193.	3.3	188
49	Magnetic Resonance Scans Should Replace Biopsies for the Diagnosis of Diffuse Brain Stem Gliomas. <i>Neurosurgery</i> , 1993, 33, 1026-1030.	0.6	185
50	Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. <i>Journal of Neurosurgery: Pediatrics</i> , 2006, 105, 444-451.	0.8	183
51	Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study. <i>Clinical Cancer Research</i> , 2013, 19, 6305-6312.	3.2	180
52	Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3069-3075.	0.8	178
53	A Multi-Institutional Retrospective Study of Intracranial Ependymoma in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 1999, 21, 203-211.	0.3	173
54	Monosomy 22 in rhabdoid or atypical tumors of the brain. <i>Journal of Neurosurgery</i> , 1990, 73, 710-714.	0.9	172

#	ARTICLE	IF	CITATIONS
55	Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A childrens cancer group phase I/II trial. <i>Cancer</i> , 1994, 74, 1827-1834.	2.0	168
56	Outcome of Children With Metastatic Medulloblastoma Treated With Carboplatin During Craniospinal Radiotherapy: A Children's Oncology Group Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2648-2653.	0.8	166
57	Pediatric Brain Tumors. <i>Neurologic Clinics</i> , 2018, 36, 533-556.	0.8	163
58	Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. , 2000, 88, 2189-2193.		160
59	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	0.8	160
60	Management of and Prognosis With Medulloblastoma. <i>Archives of Neurology</i> , 2008, 65, 1419.	4.9	157
61	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	7.7	157
62	Isochromosome 17q in primitive neuroectodermal tumors of the central nervous system. <i>Genes Chromosomes and Cancer</i> , 1989, 1, 139-147.	1.5	156
63	Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. <i>Annals of Neurology</i> , 1992, 32, 551-554.	2.8	149
64	Choroid plexus carcinoma of childhood. <i>Cancer</i> , 1992, 69, 580-585.	2.0	147
65	Final Height and Body Mass Index among Adult Survivors of Childhood Brain Cancer: Childhood Cancer Survivor Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4731-4739.	1.8	147
66	Medulloblastoma: Present Concepts of Stratification into Risk Groups. <i>Pediatric Neurosurgery</i> , 2003, 39, 60-67.	0.4	145
67	Cognitive deficits in long-term survivors of childhood brain tumors. <i>Child's Nervous System</i> , 1991, 7, 2-12.	0.6	144
68	Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas A childrens cancer group phase I/II trial. <i>Cancer</i> , 1993, 72, 1414-1421.	2.0	134
69	Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 34, 899-904.	0.4	134
70	Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. <i>Pediatric Blood and Cancer</i> , 2009, 52, 791-795.	0.8	132
71	Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas—a Pediatric Brain Tumor Consortium study. <i>Neuro-Oncology</i> , 2014, 16, 310-317.	0.6	132
72	Cerebral Gangliogliomas during Childhood. <i>Neurosurgery</i> , 1983, 13, 124-128.	0.6	131

#	ARTICLE	IF	CITATIONS
73	Results of a Prospective Randomized Trial Comparing Standard Dose Neuraxis Irradiation (3,600 Tj ETQq1 1 0.784314 rgBT /Overlock Pediatric Neurosurgery, 1996, 24, 167-177.	0.4	130
74	Leptomeningeal dissemination of primary central nervous system tumors of childhood. Annals of Neurology, 1985, 18, 217-221.	2.8	127
75	Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology Group. Pediatric Neurology, 2015, 53, 31-46.	1.0	125
76	Radiation, Atherosclerotic Risk Factors, and Stroke Risk in Survivors of Pediatric Cancer: A Report From the Childhood Cancer Survivor Study. International Journal of Radiation Oncology Biology Physics, 2013, 86, 649-655.	0.4	124
77	Correlation of Neurosurgical Subspecialization with Outcomes in Children with Malignant Brain Tumors. Neurosurgery, 2000, 47, 879-887.	0.6	123
78	Magnetic resonance imaging in the evaluation of treatment-related central nervous system damage. Cancer, 1986, 58, 635-640.	2.0	118
79	Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study. Neuro-Oncology, 2015, 17, 596-603.	0.6	118
80	Pediatric low-grade gliomas: next biologically driven steps. Neuro-Oncology, 2018, 20, 160-173.	0.6	116
81	Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncology, The, 2020, 21, e305-e316.	5.1	115
82	Biological background of pediatric medulloblastoma and ependymoma: A review from a translational research perspective. Neuro-Oncology, 2008, 10, 1040-1060.	0.6	114
83	Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatric Blood and Cancer, 2013, 60, 776-782.	0.8	114
84	Clinical, cytogenetic, and pedigree findings in 18 cases of Aicardi syndrome. American Journal of Medical Genetics Part A, 1989, 32, 461-467.	2.4	113
85	Spatial heterogeneity in medulloblastoma. Nature Genetics, 2017, 49, 780-788.	9.4	112
86	Region-specific radiotherapy and neuropsychological outcomes in adult survivors of childhood CNS malignancies. Neuro-Oncology, 2010, 12, 1173-1186.	0.6	111
87	Quality of long-term survival in young children with medulloblastoma. Journal of Neurosurgery, 1994, 80, 1004-1010.	0.9	110
88	The cerebellar mutism syndrome and its relation to cerebellar cognitive function and the cerebellar cognitive affective disorder. Developmental Disabilities Research Reviews, 2008, 14, 221-228.	2.9	109
89	The effects of adjuvant chemotherapy on growth in children with medulloblastoma. Cancer, 1992, 70, 2013-2017.	2.0	106
90	The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications. Neuro-Oncology, 2021, 23, 1215-1217.	0.6	106

#	ARTICLE	IF	CITATIONS
91	Growth Hormone Replacement Therapy in Children With Medulloblastoma: Use and Effect on Tumor Control. <i>Journal of Clinical Oncology</i> , 2001, 19, 480-487.	0.8	104
92	Postoperative cerebellar mutism syndrome following treatment of medulloblastoma: neuroradiographic features and origin. <i>Journal of Neurosurgery: Pediatrics</i> , 2010, 5, 329-334.	0.8	104
93	Marked Recovery of Vision in Children With Optic Pathway Gliomas Treated With Bevacizumab. <i>JAMA Ophthalmology</i> , 2014, 132, 111.	1.4	100
94	Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. <i>Nature Reviews Neurology</i> , 2022, 18, 515-529.	4.9	100
95	Primitive Neuroectodermal Tumors of the Central Nervous System. <i>Brain Pathology</i> , 1997, 7, 765-784.	2.1	97
96	Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1527-1534.	0.8	94
97	Incidence, Presentation, and Outcome of Spinal Cord Disease in Children With Systemic Cancer. <i>Pediatrics</i> , 1986, 78, 438-443.	1.0	94
98	Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. <i>Neuro-Oncology</i> , 2017, 19, 1279-1280.	0.6	93
99	Brain Tumors in Children. <i>Archives of Neurology</i> , 1999, 56, 421.	4.9	91
100	Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2685-2697.	0.8	91
101	Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group. <i>Cancer</i> , 2016, 122, 1928-1936.	2.0	90
102	Efficacy of adjuvant chemotherapy for patients with poor-risk medulloblastoma: A preliminary report. <i>Annals of Neurology</i> , 1988, 24, 503-508.	2.8	85
103	Chemotherapy for medulloblastoma/primitive neuroectodermal tumors of the posterior fossa. <i>Annals of Neurology</i> , 1990, 28, 823-828.	2.8	85
104	Intellectual and academic outcome following two chemotherapy regimens and radiotherapy for average-risk medulloblastoma: COG A9961. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1350-1357.	0.8	84
105	Current treatment of medulloblastoma: Recent advances and future challenges. <i>Seminars in Oncology</i> , 2004, 31, 666-675.	0.8	80
106	Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. <i>Journal of Neurosurgery</i> , 2000, 92, 249-254.	0.9	79
107	Late Morbidity and Mortality Among Medulloblastoma Survivors Diagnosed Across Three Decades: A Report From the Childhood Cancer Survivor Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 731-740.	0.8	79
108	Hyperfractionated radiotherapy for children with brainstem gliomas: A pilot study using 7,200 cGy. <i>Annals of Neurology</i> , 1990, 27, 167-173.	2.8	78

#	ARTICLE	IF	CITATIONS
109	Advances in the Diagnosis, Molecular Genetics, and Treatment of Pediatric Embryonal CNS Tumors. <i>Oncologist</i> , 2003, 8, 174-186.	1.9	78
110	Ocular late effects in childhood and adolescent cancer survivors: A report from the childhood cancer survivor study. <i>Pediatric Blood and Cancer</i> , 2010, 54, 103-109.	0.8	77
111	Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. <i>Neuro-Oncology</i> , 2011, 13, 298-306.	0.6	76
112	Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. <i>Neurology</i> , 2016, 87, 2575-2584.	1.5	76
113	Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2. <i>Clinical Cancer Research</i> , 2009, 15, 5032-5039.	3.2	74
114	Children's Oncology Group's 2013 blueprint for research: Central nervous system tumors. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1022-1026.	0.8	74
115	Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. <i>Neuro-Oncology</i> , 2018, 20, 13-23.	0.6	74
116	Pediatric low-grade gliomas: implications of the biologic era. <i>Neuro-Oncology</i> , 2017, 19, now209.	0.6	73
117	Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3446-3454.	0.8	73
118	Pineocytomas of childhood a reappraisal of natural history and response to therapy. <i>Cancer</i> , 1987, 59, 1353-1357.	2.0	72
119	Review Article : Intracranial Neoplasms in Children With Neurofibromatosis 1. <i>Journal of Child Neurology</i> , 2002, 17, 630-637.	0.7	71
120	Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine. <i>Cancer</i> , 1990, 65, 412-417.	2.0	69
121	A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. <i>Journal of Neuro-Oncology</i> , 2016, 129, 443-451.	1.4	69
122	Suprasellar germinomas in childhood. A reappraisal. <i>Cancer</i> , 1989, 63, 340-344.	2.0	68
123	Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant $\beta$ 2-interferon and hyperfractionated radiation therapy: A Childrens Cancer Group phase I/II study. , 1996, 77, 2150-2156.		68
124	Neurocognitive dysfunction in children with neurofibromatosis type 1. <i>Current Neurology and Neuroscience Reports</i> , 2003, 3, 129-136.	2.0	68
125	Phase I and Pharmacokinetic Study of the Oral Farnesyltransferase Inhibitor Lonafarnib Administered Twice Daily to Pediatric Patients With Advanced Central Nervous System Tumors Using a Modified Continuous Reassessment Method: A Pediatric Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3137-3143.	0.8	67
126	Childhood Brain Tumors: Accomplishments and Ongoing Challenges. <i>Journal of Child Neurology</i> , 2008, 23, 1122-1127.	0.7	67



#	ARTICLE	IF	CITATIONS
127	Treatment of diencephalic syndrome with chemotherapy. , 1998, 83, 166-172.		65
128	Challenges with defining response to antitumor agents in pediatric neuro-oncology: A report from the response assessment in pediatric neuro-oncology (RAPNO) working group. Pediatric Blood and Cancer, 2013, 60, 1397-1401.	0.8	64
129	Quality of Life of Adult Survivors of Germinomas Treated with Craniospinal Irradiation. Neurosurgery, 1999, 45, 1292-1298.	0.6	63
130	Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. Neuro-Oncology, 2017, 19, now242.	0.6	63
131	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precision Oncology, 2020, 4, 561-571.	1.5	62
132	Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma. JAMA Oncology, 2021, 7, 1313.	3.4	61
133	Primitive neuroectodermal tumors of the central nervous system express neuroendocrine markers and may express all classes of intermediate filaments. Human Pathology, 1990, 21, 245-252.	1.1	60
134	Chemotherapy with vincristine (VCR) and etoposide (VP-16) in children with low-grade astrocytoma. Journal of Neuro-Oncology, 1992, 14, 151-8.	1.4	59
135	A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. European Journal of Cancer, 2010, 46, 3287-3293.	1.3	59
136	Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy. Neuro-Oncology, 2004, 6, 113-118.	0.6	58
137	Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma. Cancer, 2005, 104, 2862-2871.	2.0	58
138	Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 776-783.	0.8	58
139	Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. Journal of Clinical Oncology, 2018, 36, 3388-3395.	0.8	58
140	Chemotherapy for low-grade gliomas. Child's Nervous System, 1999, 15, 506-513.	0.6	57
141	Handheld Optical Coherence Tomography During Sedation in Young Children With Optic Pathway Gliomas. JAMA Ophthalmology, 2014, 132, 265.	1.4	57
142	Results of the treatment of children with recurrent gliomas with lomustine and vincristine. Cancer, 1988, 61, 896-902.	2.0	55
143	A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. Journal of Neuro-Oncology, 2013, 114, 173-179.	1.4	55
144	High dose systemic methotrexate-associated acute neurologic dysfunction. Medical and Pediatric Oncology, 1983, 11, 159-161.	1.0	54

#	ARTICLE	IF	CITATIONS
145	NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. <i>Journal of Clinical Oncology</i> , 2021, 39, 797-806.	0.8	54
146	Management of Children with Primitive Neuroectodermal Tumors of the Posterior Fossa/Medulloblastoma. <i>Pediatric Neurosurgery</i> , 1985, 12, 272-282.	0.4	53
147	A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1. <i>Neurology</i> , 2017, 88, 1584-1589.	1.5	53
148	A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). <i>Pediatric Blood and Cancer</i> , 2013, 60, 71-76.	0.8	52
149	Pilocytic astrocytomas. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 329-344.	1.0	52
150	MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry. <i>Neuro-Oncology</i> , 2020, 22, 1647-1657.	0.6	51
151	Vascular malformation with radiation vasculopathy after treatment of chiasmatic/hypothalamic glioma. <i>Cancer</i> , 1992, 70, 887-893.	2.0	50
152	An integrated approach to the treatment of chiasmatic-hypothalamic gliomas. <i>Journal of Neuro-Oncology</i> , 1996, 28, 167-83.	1.4	50
153	A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation. <i>Acta Neuropathologica</i> , 2015, 130, 575-585.	3.9	50
154	Oligodendroglioma of the posterior fossa in childhood. <i>Cancer</i> , 1985, 56, 195-199.	2.0	49
155	Central Nervous System Tumors. <i>Pediatric Clinics of North America</i> , 2008, 55, 121-145.	0.9	48
156	Auditory complications in childhood cancer survivors: A report from the childhood cancer survivor study. <i>Pediatric Blood and Cancer</i> , 2011, 57, 126-134.	0.8	48
157	Early cystic/necrotic changes after hyperfractionated radiation therapy in children with brain stem gliomas data from the childrens cancer group. <i>Cancer</i> , 1993, 71, 2666-2674.	2.0	47
158	Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET). <i>Current Treatment Options in Neurology</i> , 2013, 15, 593-606.	0.7	47
159	Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 165-173.	15.2	46
160	Intracranial embryonal cell carcinoma. <i>Cancer</i> , 1984, 54, 520-524.	2.0	45
161	Results of a pilot study of low-dose craniospinal radiation therapy plus chemotherapy for children younger than 5 years with primitive neuroectodermal tumors. <i>Cancer</i> , 1993, 71, 2647-2652.	2.0	45
162	A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. <i>Cancer</i> , 2005, 104, 1968-1974.	2.0	45

#	ARTICLE	IF	CITATIONS
163	A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. <i>Neuro-Oncology</i> , 2020, 22, 1527-1535.	0.6	45
164	Acute Mental Status Changes in Children With Systemic Cancer. <i>Pediatrics</i> , 1990, 85, 353-360.	1.0	45
165	Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2014, 16, 1554-1559.	0.6	44
166	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. <i>Neuro-Oncology</i> , 2020, 22, 773-784.	0.6	44
167	Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue. <i>Pediatric Blood and Cancer</i> , 2007, 48, 278-284.	0.8	43
168	Primary spinal cord tumors of childhood: effects of clinical presentation, radiographic features, and pathology on survival. <i>Journal of Neuro-Oncology</i> , 2009, 95, 259-269.	1.4	43
169	Microphthalmia and chorioretinal lesions in a girl with an Xp22.2-pter deletion and partial 3p trisomy: Clinical observations relevant to aicardi syndrome gene localization. <i>American Journal of Medical Genetics Part A</i> , 1990, 37, 182-186.	2.4	42
170	Phase I Clinical Trial of Mafosfamide in Infants and Children Aged 3 Years or Younger With Newly Diagnosed Embryonal Tumors: A Pediatric Brain Tumor Consortium Study (PBTC-001). <i>Journal of Clinical Oncology</i> , 2005, 23, 525-531.	0.8	42
171	Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: Report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2014, 61, 102-106.	0.8	42
172	Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report. <i>Neuro-Oncology</i> , 2018, 20, 132-142.	0.6	42
173	Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review. <i>Child's Nervous System</i> , 2014, 30, 979-990.	0.6	41
174	Late recurrence of primitive neuroectodermal Tumor/Medulloblastoma. <i>Cancer</i> , 1988, 62, 826-830.	2.0	40
175	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	0.8	40
176	SHH inhibitors for the treatment of medulloblastoma. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 763-770.	1.4	39
177	Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. <i>Pediatric Blood and Cancer</i> , 2009, 52, 169-176.	0.8	38
178	Medulloblastoma and primitive neuroectodermal tumors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 105, 529-548.	1.0	38
179	Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 275-282.	1.1	37
180	Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. <i>Cancer</i> , 2005, 104, 1281-1287.	2.0	37

#	ARTICLE	IF	CITATIONS
181	Advances in the Management of Low-Grade Gliomas. <i>Current Oncology Reports</i> , 2014, 16, 398.	1.8	36
182	Autism-associated Nf1 deficiency disrupts corticocortical and corticostriatal functional connectivity in human and mouse. <i>Neurobiology of Disease</i> , 2019, 130, 104479.	2.1	36
183	Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in <i>BRAF</i> V600E mutant pediatric low-grade glioma (pLGG).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA2002-LBA2002.	0.8	35
184	Neurologic complications in children with soft tissue and osseous sarcoma. <i>Cancer</i> , 1989, 64, 2600-2603.	2.0	34
185	Subgroup and subtype-specific outcomes in adult medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 859-871.	3.9	34
186	Chemotherapy: Low-Grade Gliomas of the Hypothalamus and Thalamus. <i>Pediatric Neurosurgery</i> , 2000, 32, 259-263.	0.4	33
187	A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study. <i>Neuro-Oncology</i> , 2015, 17, 1132-1138.	0.6	33
188	Review Article : Therapy for Plexiform Neurofibromas in Children With Neurofibromatosis 1: An Overview. <i>Journal of Child Neurology</i> , 2002, 17, 638-641.	0.7	32
189	Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach. <i>Journal of Neuro-Oncology</i> , 2017, 133, 119-128.	1.4	32
190	Pediatric Brain Tumors and Epilepsy. <i>Seminars in Pediatric Neurology</i> , 2012, 19, 3-8.	1.0	30
191	Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945. <i>Journal of Neuro-Oncology</i> , 2015, 121, 573-581.	1.4	30
192	<i>MYC</i> Drives Group 3 Medulloblastoma through Transformation of Sox2+ Astrocyte Progenitor Cells. <i>Cancer Research</i> , 2019, 79, 1967-1980.	0.4	29
193	Progress and Challenges in Childhood Brain Tumors. <i>Journal of Neuro-Oncology</i> , 2005, 75, 239-242.	1.4	28
194	Antioxidant enzyme polymorphisms and neuropsychological outcomes in medulloblastoma survivors: a report from the Childhood Cancer Survivor Study. <i>Neuro-Oncology</i> , 2012, 14, 1018-1025.	0.6	27
195	Visual Outcomes in Children With Neurofibromatosis Type 1 and Orbitotemporal Plexiform Neurofibromas. <i>American Journal of Ophthalmology</i> , 2013, 155, 1089-1094.e1.	1.7	27
196	Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26838.	0.8	27
197	An animal model to detect the neuropsychological toxicity of anticancer agents. <i>Medical and Pediatric Oncology</i> , 1989, 17, 216-221.	1.0	26
198	Primary central nervous system tumors in children. <i>Current Treatment Options in Neurology</i> , 1999, 1, 395-408.	0.7	24

#	ARTICLE	IF	CITATIONS
199	Liquid biopsy for pediatric central nervous system tumors. <i>Npj Precision Oncology</i> , 2018, 2, 29.	2.3	24
200	Etoposide with or without mannitol for the treatment of recurrent or primarily unresponsive brain tumors: a Children's Cancer Group Study, CCG-9881. <i>Journal of Neuro-Oncology</i> , 1999, 45, 47-54.	1.4	23
201	Case-based review: pediatric medulloblastoma. <i>Neuro-Oncology Practice</i> , 2017, 4, 138-150.	1.0	22
202	Quantitative MRI criteria for optic pathway enlargement in neurofibromatosis type 1. <i>Neurology</i> , 2016, 86, 2264-2270.	1.5	21
203	Biologically Targeted Therapeutics in Pediatric Brain Tumors. <i>Pediatric Neurology</i> , 2012, 46, 203-211.	1.0	20
204	Medulloblastoma: Toward Biologically Based Management. <i>Seminars in Pediatric Neurology</i> , 2015, 22, 6-13.	1.0	20
205	Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. <i>Journal of Neuro-Oncology</i> , 2015, 121, 217-224.	1.4	20
206	MB-109PRELIMINARY RESULTS OF COG ACNS0331: A PHASE III TRIAL OF INVOLVED FIELD RADIOTHERAPY (IFRT) AND LOW DOSE CRANIOSPINAL IRRADIATION (LD-CSI) WITH CHEMOTHERAPY IN AVERAGE RISK MEDULLOBLASTOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP. <i>Neuro-Oncology</i> , 2016, 18, iii122-iii122.	0.6	20
207	Medulloblastoma. <i>Current Opinion in Neurology</i> , 1999, 12, 681-685.	1.8	20
208	Proteomic profiling of high risk medulloblastoma reveals functional biology. <i>Oncotarget</i> , 2015, 6, 14584-14595.	0.8	20
209	Hypothalamic-Pituitary and Other Endocrine Surveillance Among Childhood Cancer Survivors. <i>Endocrine Reviews</i> , 2022, 43, 794-823.	8.9	20
210	Radiation-induced neurocognitive decline: The risks and benefits of reducing the amount of whole-brain irradiation. <i>Current Neurology and Neuroscience Reports</i> , 2002, 2, 131-133.	2.0	19
211	Central nervous system and langerhans' cell histiocytosis. <i>Medical and Pediatric Oncology</i> , 1990, 18, 325-328.	1.0	17
212	Chemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors. <i>Oncologist</i> , 1996, 1, 381-393.	1.9	17
213	Magnetic resonance imaging in the evaluation of intracranial tumors of childhood. <i>Cancer</i> , 1985, 56, 1767-1772.	2.0	16
214	Spinal cord compression in widely metastatic Wilms' tumor. Paraplegia in two children with anaplastic wilms' tumor. <i>Cancer</i> , 1992, 69, 2726-2730.	2.0	16
215	Computerized cognitive training for children with neurofibromatosis type 1: A pilot resting-state fMRI study. <i>Psychiatry Research - Neuroimaging</i> , 2017, 266, 53-58.	0.9	16
216	Fatal brain stem necrosis after standard posterior fossa radiation and aggressive chemotherapy for metastatic medulloblastoma. <i>Cancer</i> , 1993, 71, 4111-4117.	2.0	15

#	ARTICLE	IF	CITATIONS
217	Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy. <i>Current Neurology and Neuroscience Reports</i> , 2007, 7, 129-132.	2.0	15
218	Targeted therapy for infants with diencephalic syndrome: A case report and review of management strategies. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26917.	0.8	15
219	Optic pathway "hypothalamic glioma hemorrhage: a series of 9 patients and review of the literature. <i>Journal of Neurosurgery</i> , 2018, 129, 1407-1415.	0.9	14
220	NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. <i>Neuro-Oncology</i> , 2018, 20, i143-i143.	0.6	14
221	Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1. <i>Neurology: Genetics</i> , 2021, 7, e616.	0.9	14
222	Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitors. <i>Developmental Cell</i> , 2021, 56, 2871-2885.e6.	3.1	14
223	Risk Stratification of Medulloblastoma: A Paradigm for Future Childhood Brain Tumor Management Strategies. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 124-126.	2.0	13
224	Radiation therapy quality in CCG/POG intergroup 9961: implications for craniospinal irradiation and the posterior fossa boost in future medulloblastoma trials. <i>Frontiers in Oncology</i> , 2012, 2, 185.	1.3	13
225	High Incidence of Venous Occlusive Disease With Myeloablative Chemotherapy Following Craniospinal Irradiation in Children With Newly Diagnosed High-Risk CNS Embryonal Tumors: A Report From the Children's Oncology Group (CCG99702). <i>Pediatric Blood and Cancer</i> , 2016, 63, 1563-1570.	0.8	13
226	Cerebellar sclerosis in pediatric cancer patients. <i>Journal of Neuro-Oncology</i> , 1987, 4, 353-60.	1.4	12
227	Alternative Therapies for Children with Brain Stem Gliomas: Immunotherapy and Gene Therapy. <i>Pediatric Neurosurgery</i> , 1996, 24, 217-222.	0.4	12
228	Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 87-108.	0.9	11
229	MRI Features of Histologically Diagnosed Supratentorial Primitive Neuroectodermal Tumors and Pineoblastomas in Correlation with Molecular Diagnoses and Outcomes: A Report from the Children's Oncology Group ACNS0332 Trial. <i>American Journal of Neuroradiology</i> , 2019, 40, 1796-1803.	1.2	11
230	Molecular-Targeted Therapy for Childhood Brain Tumors: A Moving Target. <i>Journal of Child Neurology</i> , 2020, 35, 791-798.	0.7	11
231	Current approaches to CNS tumors in infants and very young children. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 681-690.	1.4	10
232	Neurotoxicity of Biologically Targeted Agents in Pediatric Cancer Trials. <i>Pediatric Neurology</i> , 2012, 46, 212-221.	1.0	10
233	A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10065-10065.	0.8	10
234	PROGRESS IN THE TREATMENT OF CHILDHOOD BRAIN TUMORS: No Room for Complacency. <i>Pediatric Hematology and Oncology</i> , 2007, 24, 79-84.	0.3	9

#	ARTICLE	IF	CITATIONS
235	Impact of Molecular Biology Studies on the Understanding of Brain Tumors in Childhood. <i>Current Oncology Reports</i> , 2012, 14, 206-212.	1.8	9
236	Update on Pediatric Brain Tumors: the Molecular Era and Neuro-immunologic Beginnings. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 30.	2.0	9
237	Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 245-249.	1.7	9
238	Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28833.	0.8	9
239	Characteristics of patients $\geq 10$ years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. <i>Neuro-Oncology</i> , 2022, 24, 141-152.	0.6	9
240	Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. <i>Neuro-Oncology</i> , 2022, 24, 821-833.	0.6	9
241	Dabrafenib + trametinib (dab + tram) in relapsed/refractory (r/r) <i>BRAF</i> V600E mutant pediatric high-grade glioma (pHGG): Primary analysis of a phase II trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2009-2009.	0.8	9
242	Radiation Therapy for Pediatric Low-Grade Gliomas: Survival and Sequelae. <i>Current Neurology and Neuroscience Reports</i> , 2010, 10, 10-13.	2.0	8
243	A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B). <i>Journal of Clinical Oncology</i> , 2013, 31, 2035-2035.	0.8	8
244	Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma. <i>Current Neurology and Neuroscience Reports</i> , 2007, 7, 130, 132.	2.0	8
245	Alternative treatments for childhood brain tumors. <i>Child's Nervous System</i> , 1999, 15, 789-794.	0.6	7
246	Pediatric diffuse leptomeningeal glioneuronal tumor: Two clinical cases of successful targeted therapy. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28478.	0.8	7
247	Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas. <i>Scientific Reports</i> , 2020, 10, 10954.	1.6	7
248	The experience of successful treatment of <i>ETV6-NTRK3</i> -positive infant glioblastoma with entrectinib. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab022.	0.4	7
249	Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: a case report. <i>Oncotarget</i> , 0, 7, 42837-42842.	0.8	7
250	Craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. <i>Current Neurology and Neuroscience Reports</i> , 2007, 7, 130-2.	2.0	7
251	Understanding the molecular complexity of medulloblastoma. <i>Nature Reviews Neurology</i> , 2012, 8, 539-540.	4.9	6
252	New treatment modalities in NF-related neuroglial tumors. <i>Child's Nervous System</i> , 2020, 36, 2377-2384.	0.6	6

#	ARTICLE	IF	CITATIONS
253	Seven-Year Experience From the National Institute of Neurological Disorders and Strokeâ€œSupported Network for Excellence in Neuroscience Clinical Trials. JAMA Neurology, 2020, 77, 755.	4.5	6
254	Unsupervised MRI Homogenization: Application to Pediatric Anterior Visual Pathway Segmentation. Lecture Notes in Computer Science, 2020, 12436, 180-188.	1.0	6
255	New insights into childhood ependymomas. Current Neurology and Neuroscience Reports, 2005, 5, 107-109.	2.0	5
256	Medulloblastoma/Primitive Neuroectodermal Tumor and Germ Cell Tumors. Hematology/Oncology Clinics of North America, 2012, 26, 881-895.	0.9	5
257	A Review of Secondary Central Nervous System Tumors After Treatment of a Primary Pediatric Malignancy. Seminars in Pediatric Neurology, 2012, 19, 43-48.	1.0	5
258	A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas. Journal of Neuro-Oncology, 2020, 149, 437-445.	1.4	5
259	Child Neurology: The Role of the Pediatric Neurologist Both Within and Outside the Academic Setting. Pediatric Neurology, 2011, 44, 10-11.	1.0	4
260	Response to Harreld re: â€œResponse assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology Committeeâ€œ. Neuro-Oncology, 2018, 20, 144-145.	0.6	4
261	Two clinically distinct cases of infant hemispheric glioma carrying <i>ZCCHC8:ROS1</i> fusion and responding to entrectinib. Neuro-Oncology, 2022, 24, 1029-1031.	0.6	4
262	Characteristics of children â‰¥36 months of age with DIPG: A report from the international DIPG registry. Neuro-Oncology, 2022, 24, 2190-2199.	0.6	4
263	New treatments in pediatric brain tumors. Current Treatment Options in Neurology, 2004, 6, 377-389.	0.7	3
264	Reduction of health status 7 years after addition of chemotherapy to cranio-spinal irradiation for medulloblastoma: A follow-up study on PNET-3 trial survivors. Current Neurology and Neuroscience Reports, 2008, 8, 111-113.	2.0	3
265	NFM-01. NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY. Neuro-Oncology, 2018, 20, i142-i142.	0.6	3
266	LGG-02. A PHASE II PROSPECTIVE TRIAL OF SELUMETINIB IN CHILDREN WITH RECURRENT/PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (PLGG) WITH A FOCUS UPON OPTIC PATHWAY/HYPOTHALAMIC TUMORS AND VISUAL ACUITY OUTCOMES: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY, PBTC-029B. Neuro-Oncology, 2019, 21, ii98-ii99.	0.6	3
267	Multiâ€œinstitutional analysis of treatment modalitiâ€œs in basal ganglia and thalamic germinoma. Pediatric Blood and Cancer, 2021, 68, e29172.	0.8	3
268	The impact of molecular analysis on the survival of children with embryonal tumors. Translational Pediatrics, 2016, 5, 5-8.	0.5	3
269	Is postoperative chemotherapy alone sufficient to treat young children with medulloblastoma?. Nature Clinical Practice Oncology, 2005, 2, 386-387.	4.3	2
270	Immunotherapy Approaches for Pediatric CNS Tumors and Associated Neurotoxicity. Pediatric Neurology, 2020, 107, 7-15.	1.0	2



#	ARTICLE	IF	CITATIONS
271	Computerized Working Memory Training for Children With Neurofibromatosis Type 1 (NF1): A Pilot Study. <i>Journal of Child Neurology</i> , 2021, 36, 088307382110380.	0.7	2
272	Translational/Clinical Studies in Children and Adults with Neurofibromatosis Type 1. , 2012, , 625-657.		2
273	MBCL-16. EFFICACY OF CARBOPLATIN GIVEN CONCOMITANTLY WITH RADIATION AND ISOTRETINOIN AS A PRO-APOPTOTIC AGENT IN MAINTENANCE THERAPY IN HIGH-RISK MEDULLOBLASTOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP. <i>Neuro-Oncology</i> , 2020, 22, iii391-iii391.	0.6	2
274	OTHR-08. Pediatric Neurologic Assessment in Neuro-oncology (pNANO) Scale: A tool to assess neurologic function for Response Assessment in Neuro-oncology (RAPNO). <i>Neuro-Oncology</i> , 2022, 24, i148-i148.	0.6	2
275	Gene expression profiling to analyze embryonal tumors of the central nervous system. <i>Current Neurology and Neuroscience Reports</i> , 2003, 3, 117-119.	2.0	1
276	Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children. <i>Current Neurology and Neuroscience Reports</i> , 2009, 9, 94-96.	2.0	1
277	Center for Neuroscience and Behavioral Medicine: An Innovative Administrative Structure and Possible Paradigm for the Future. <i>Pediatric Neurology</i> , 2011, 44, 1-9.	1.0	1
278	Temozolomide for Pediatric High-Grade Gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 111-113.	2.0	1
279	Anaplastic Ependymoma in a Child With Sickle Cell Anemia: A Case Report Highlighting Treatment Challenges for Young Children With Central Nervous System Tumors and Underlying Vasculopathy. <i>Pediatric Blood and Cancer</i> , 2016, 63, 547-550.	0.8	1
280	Pediatric Neuro-oncology. , 2017, , 957-962.		1
281	DIPG-69. CHARACTERISTICS OF PATIENTS ≥ 10 YEARS OF AGE WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i63-i63.	0.6	1
282	DIPG-51. BLACKFYNN: A SECURE, CLOUD-BASED PLATFORM FOR SHARING AND ANALYZING RESEARCH READY DATA FOR PEDIATRIC CNS CANCERS. <i>Neuro-Oncology</i> , 2018, 20, i59-i59.	0.6	1
283	Integrated analysis of pediatric low-grade glioma: clinical implications and the path forward. <i>Neuro-Oncology</i> , 2020, 22, 1413-1414.	0.6	1
284	JNO special issue: an update on pediatric neuro-oncology. <i>Journal of Neuro-Oncology</i> , 2020, 150, 1-4.	1.4	1
285	Tumors of the Brain and Spine. , 2012, , 1339-1387.		1
286	Health and functional status of long-term adult medulloblastoma/PNet survivors: A report from the Childhood Cancer Survivor Study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9515-9515.	0.8	1
287	Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry. <i>Neuro-Oncology</i> , 2022, , .	0.6	1
288	IMMU-19. Outcomes of Pediatric Patients with High-Risk CNS Tumors Treated with Multi-tumor associated antigen specific T cell (TAA-T) therapy: the ReMIND trial. <i>Neuro-Oncology</i> , 2022, 24, i85-i86.	0.6	1

#	ARTICLE	IF	CITATIONS
289	Infantile suprasellar tumor diagnosed as a pineoblastoma RB1 subgroup and treatment challenges: A pediatric SNO Molecular Tumor Board. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	1
290	Comment: Intracranial ependymomas in children. <i>Medical and Pediatric Oncology</i> , 1998, 30, 330-330.	1.0	0
291	Preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma. <i>Current Neurology and Neuroscience Reports</i> , 2004, 4, 127-128.	2.0	0
292	Journal of Neuro-Oncology: Childhood Brain Tumors. <i>Journal of Neuro-Oncology</i> , 2005, 75, 237-237.	1.4	0
293	Pediatric Brain Tumors (An Overview). <i>Pediatric Cancer</i> , 2012, , 61-73.	0.0	0
294	Parental and physician attitudes toward medulloblastoma treatment. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1149-1150.	0.8	0
295	Cingulate Apparent Diffusion Coefficient measurements in children with Neurofibromatosis type 1. <i>Journal of Pediatric Neuroradiology</i> , 2015, 03, 121-126.	0.1	0
296	DIPG-53. COMPREHENSIVE CLINICAL AND MOLECULAR ANALYSIS OF PEDIATRIC THALAMIC GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, i59-i60.	0.6	0
297	CRAN-16. IMPORTANCE OF SURGICAL INTERVENTION IN RECOVERY OF VISUAL FUNCTION IN A TEENAGER WITH AN ACIDOPHILIC STEM CELL ADENOMA. <i>Neuro-Oncology</i> , 2018, 20, i39-i40.	0.6	0
298	PDTM-13. OVEREXPRESSION OF MYC ALONE IS SUFFICIENT TO INITIATE GROUP 3 MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi206-vi206.	0.6	0
299	PDTM-15. IDENTIFICATION AND CHARACTERIZATION OF WILMSâ€™ TUMOR PROTEIN IN PEDIATRIC MIDLINE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi206-vi207.	0.6	0
300	EMBR-01. MOLECULAR AND CLINICAL HETEROGENEITY IN HISTOLOGICALLY-DIAGNOSED CNS-PNET PATIENTS PROSPECTIVELY TREATED AS A SINGLE ENTITY: A REPORT FROM THE CHILDRENâ€™S ONCOLOGY GROUP ACNS0332 TRIAL. <i>Neuro-Oncology</i> , 2018, 20, i68-i69.	0.6	0
301	Chemotherapy for Medulloblastomaâ€”Childhood. , 2018, , 569-583.		0
302	DIPG-70. CLINICAL, RADIOLOGICAL, PATHOLOGICAL AND MOLECULAR CHARACTERISTICS OF CHILDREN <3 YEARS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i63-i63.	0.6	0
303	EMBR-02. OLIG2 REPRESENTS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN MYC-AMPLIFIED MEDULLOBLASTOMA RELAPSE AND METASTASIS. <i>Neuro-Oncology</i> , 2021, 23, i5-i6.	0.6	0
304	Event-Free Survival of Children with Average-Risk Medulloblastoma: Treatment with Craniospinal Radiation Followed by Adjuvant Chemotherapy. <i>Pediatric Cancer</i> , 2013, , 93-101.	0.0	0
305	The Effectiveness of Chemotherapy for Childhood Medulloblastoma (&lt;Special Issue&gt;Topics of) Tj ETQq1 1 0.784314 rgBT /Overl	0.0	0
306	MBCL-15. IMPACT OF MOLECULAR SUBGROUPS ON OUTCOMES FOLLOWING RADIATION TREATMENT RANDOMIZATIONS FOR AVERAGE RISK MEDULLOBLASTOMA: A PLANNED ANALYSIS OF CHILDRENâ€™S ONCOLOGY GROUP (COG) ACNS0331. <i>Neuro-Oncology</i> , 2020, 22, iii391-iii391.	0.6	0

#	ARTICLE	IF	CITATIONS
307	LGG-26. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR (DLGNT) IN CHILDREN: DIFFERENT CLINICAL PRESENTATIONS AND OUTCOMES. <i>Neuro-Oncology</i> , 2020, 22, iii371-iii371.	0.6	0
308	GCT-23. MULTI-INSTITUTIONAL ANALYSIS OF TREATMENT MODALITIES IN BASAL GANGLIA AND THALAMIC GERMINOMA. <i>Neuro-Oncology</i> , 2020, 22, iii332-iii332.	0.6	0
309	NIMG-11. VOLUMETRIC ENDPOINTS IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): COMPARISON TO CROSS-SECTIONAL MEASURES AND CORRELATION WITH OUTCOMES. <i>Neuro-Oncology</i> , 2021, 23, vi129-vi130.	0.6	0
310	CTNI-10. MAINTENANCE CHEMOTHERAPY USING BEVACIZUMAB FOR NEUROFIBROMATOSIS 2 PATIENTS WITH HEARING LOSS AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY (NF104). <i>Neuro-Oncology</i> , 2020, 22, ii43-ii43.	0.6	0
311	Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy. <i>Current Neurology and Neuroscience Reports</i> , 2007, 7, 129, 132.	2.0	0
312	DIPG-48. MRI volumetric and machine learning based analyses predict survival outcome in pediatric diffuse midline glioma. <i>Neuro-Oncology</i> , 2022, 24, i29-i29.	0.6	0
313	IMG-08. Response assessment for pediatric craniopharyngioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Neuro-Oncology</i> , 2022, 24, i78-i78.	0.6	0
314	DIPG-47. TSO500ctDNA sequencing reveals oncogenic mutations and copy number variations in the liquid biome of children with diffuse midline glioma. <i>Neuro-Oncology</i> , 2022, 24, i29-i29.	0.6	0